MPLT at a glance
MapLight Therapeutics, Inc. (MPLT, SEC CIK 1770069) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding MapLight Therapeutics, Inc. (MPLT) shares worth $265.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hanson Kristopher on September 16, 2026 of 16,509 shares at $11.67 per share.
- In the last 90 days, MPLT insiders reported 6 open-market purchases ($65.5M) and 46 open-market sales ($11.6M) on Form 4, a net purchase of $53.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 6 buys · 46 sells
- Net +$53.9M
- 13F holders
- 21 funds
- $265.4M · +5 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 1.01 · Item 2.02 · Item 3.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered lease risk: South San Francisco facility expected to commence in May 2027, subject to landlord tenant improvements
- Most materially updated operational risk: Redwood City lease termination moved expiration from June 2031 to September 2027
- Regulatory risk: ML-007C-MA requires multiple clinical trials and regulatory approval before commercialization
- Near-term performance risk: Research and development expense increased to $107.1 million from $46.6 million year-to-date
- Liquidity risk: Accumulated deficit reached $481.4 million, with additional capital required despite $351.3 million available funding runway beyond twelve months
AI summary of the MPLT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- No substantive material agreement terms disclosed in the provided Item 1.01 excerpt
- Investor impact cannot be assessed without the referenced agreement or additional filing details
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 filing contains only an exhibit incorporation disclaimer
- No operating results, financial figures, or fiscal-year performance details available in the provided text
Item 3.02: Unregistered Sales of Equity Securities
- Purchase Agreement covers securities to be sold and issued by MapLight Therapeutics
- Item 3.02 signals an unregistered equity issuance, potentially creating dilution for existing shareholders
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation for investor and analyst meetings
- Presentation furnished as Exhibit 99.3 and available on the company website
Item EX-99.1: Item EX-99.1
- Positive Phase 2 ZEPHYR results support planned registrational Phase 3 ZEPHYR-2 in schizophrenia, with topline results expected in 2028
- ML-007C-MA advanced as the lead asset across schizophrenia and ADP; VISTA enrollment ongoing with results expected in the second half of 2027
Item 7.01: Regulation FD Disclosure
- July 27, 2026 conference call covering topline ZEPHYR Phase 2 results
- ML-007C-MA evaluated in inpatient adults with schizophrenia and acute psychosis exacerbation
Item 8.01: Other Events
- July 27, 2026 press release announced results from MapLight’s ZEPHYR clinical trial
- Trial results may affect investors’ assessment of development progress and regulatory prospects
Item EX-99.1: Item EX-99.1
- Phase 2 ZEPHYR met its primary endpoint: 210/3 mg BID reduced PANSS by 4.5 points versus placebo, effect size 0.37, p=0.015
- Prespecified cognitive improvement supports differentiation: effect size 0.51, 0.44-point benefit, p=0.041, independent of psychosis reduction
Item 5.07: Submission of Matters to a Vote of Security Holders
- 86.56% shareholder participation, with 36,883,750 of 42,610,079 shares represented
- Martin Babler, Troy Cox, and George Pavlov elected as directors through the 2029 annual meeting
AI summaries of MPLT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MPLT
Don't miss the next MPLT filing
- Alerts as it files. A push when MPLT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MPLT, by share count.
- Ask anything. An AI agent that reads every MPLT filing and answers with sources.
MPLT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hanson Kristopher | Sell | Sep 16, 2026 | 16,509 | $11.67 |
| GILLIS JONATHAN | A | Aug 17, 2026 | 2,222 | - |
| Kroeger Christopher A. | A | Aug 17, 2026 | 93,955 | - |
| Kroeger Christopher A. | A | Aug 17, 2026 | 23,145 | - |
| Kreitzer Anatol | A | Aug 17, 2026 | 6,020 | - |
| GILLIS JONATHAN | A | Aug 17, 2026 | 6,020 | - |
| Foff Erin Pennock | A | Aug 17, 2026 | 13,360 | - |
| GILLIS JONATHAN | A | Aug 17, 2026 | 24,455 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | - | -$82.9M | -$169.1M |
| Net Income | - | -$77.6M | -$161.2M |
| Balance Sheet | |||
| Total Assets | - | $136.9M | $479.5M |
| Equity | -$117.6M | -$193.6M | $458.4M |
| ROE | - | 40.1% | -35.2% |
| Per Share | |||
| EPS | - | $-105.38 | $-18.56 |
| Cash Flow | |||
| Operating CF | - | -$78.8M | -$138.1M |
| CapEx | - | $770K | $473K |
Source: XBRL data in MapLight Therapeutics, Inc. (MPLT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MPLT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $265.4M |
| Q1 2026 | 16 | $103.7M |
| Q4 2025 | 16 | $81.8M |
- T. Rowe Price Group+1.31M (+1162%)
- FMR LLC (Fidelity)+619.1K (+303%)
- State Street Corp+513.0K (+151%)
- Vanguard Capital Management LLC+64.3K (+9%)
- Bank of America Corp+35.6K (+189%)
- BlackRock−314.6K (-23%)
- Goldman Sachs Group−46.6K (-2%)
- Northern Trust−29.5K (-20%)
- Vanguard Portfolio Management LLC−15.8K (-14%)
- BNY Mellon−9.1K (-23%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 53 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MPLT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| SC 13G | Aug 20, 2026 | - | - | |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MPLT SEC filings: frequently asked questions
Are MPLT insiders buying or selling?
In the last 90 days, MapLight Therapeutics, Inc. (MPLT) officers, directors and 10% owners reported 6 open-market purchases worth $65.5 million by 2 insiders and 46 open-market sales worth $11.6 million by 6 insiders on Form 4, a net purchase of $53.9 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MPLT stock?
As of June 30, 2026, the largest MapLight Therapeutics, Inc. (MPLT) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($69.8 million), T. Rowe Price Group ($51.0 million), BlackRock ($36.7 million), State Street Corp ($30.5 million), FMR LLC (Fidelity) ($29.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did MPLT report in its latest 8-K?
MapLight Therapeutics, Inc. (MPLT) filed an 8-K on August 13, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities) and Item 7.01 (Regulation FD Disclosure). No substantive material agreement terms disclosed in the provided Item 1.01 excerpt.
What are the latest MPLT SEC filings?
MapLight Therapeutics, Inc. (MPLT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 18, 2026.
What is MPLT's SEC CIK number?
MapLight Therapeutics, Inc. (MPLT)'s SEC Central Index Key (CIK) is 1770069. EDGAR lists every MPLT filing under that number.
Ask anything about MPLT
The research agent reads MPLT's filings, financials, insider trades and 13F holders, then answers with sources.